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Background: Understanding cognitive and biological mechanisms of PTSD
treatment can help refine treatments and increase rates of response. Methods:
Thirty-six veterans with PTSD were randomly assigned to receive Prolonged
exposure therapy (PE) or Present-Centered therapy (PCT). We examined symp-
toms, trauma-related cognitions, and two indices of HPA axis function (corti-
sol awakening response and cortisol response to a script-driven imagery task).
Results: Thirty veterans started treatment and 26 completed. PE resulted in
significantly more symptom reduction than PCT (P = .008). High treatment
responders collapsed across treatments showed nominally higher cortisol levels
measured at pretreatment 30 min after trauma script exposure compared to low
responders (P= .08). At midtreatment, high treatment responders showed higher
cortisol levels throughout the imagery task (Ps = .03–.04). There were no dif-
ferences between high and low treatment responders at posttreatment. Thoughts
of incompetence (F (1.6, 35.8) = 16.8, P = .000) and a dangerous world (F
(1.3, 29.9) = 8.2, P = .004) significantly improved over time in high treatment
responders but showed no change in low responders. Script-associated cortisol re-
sponse prior to treatment and reductions in thoughts of incompetence accounted
for 83% of the variance in reductions in PTSD severity with PE. Conclusions:
Both increased cortisol response to personal trauma script prior to PTSD therapy
and reductions in cognitive symptoms of PTSD were significantly and uniquely
related to reductions in the core symptoms of PTSD in PE. However, contrary to
our hypotheses, cortisol measures were not related to cognitive changes. Depres-
sion and Anxiety 32:204–212, 2015. C© 2014 Wiley Periodicals, Inc.
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Mechanistic research examining the biological and
psychological factors involved in effective PTSD
treatment is a critical area of developing research.
Understanding these mechanisms can help to reﬁne
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treatments, improve efﬁcacy and efﬁciency, and increase
rates of response. Among themost studied biological sys-
tems involved in PTSD is the hypothalamic–pituitary–
adrenal (HPA) axis with signiﬁcant focus on cortisol.
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Patients with PTSD have been consistently shown to
haveHPA axis abnormalities, primarily enhanced gluco-
corticoid receptor sensitivity leading to enhanced nega-
tive feedback and, less consistently, hypocortisolemia[1–3]
and ﬂattened diurnal cortisol rhythms.[4] There is evi-
dence that glucocorticoids can inﬂuence the course of ill-
ness inPTSD.However, it remains unclear as towhether
HPA axis dysregulation is an etiologic/pathophysiologic
factor in PTSD, a biomarker of trait vulnerability, or
an active agent shaping illness manifestation and per-
haps recovery by promoting plasticity of speciﬁc brain
circuits.
AlthoughProlongedExposure therapy (PE) is a highly
effective treatment[5],many patients drop out of PEor do
not remit from PTSD,[6] suggesting that greater under-
standing of the processes involved could direct us toward
better outcomes. The components of PE include expo-
sure and emotional processing. Repeated exposures to
the memory itself and cues in life (imaginal and in vivo
exposure) lead to extinction/desensitization of emotional
responses possibly through inhibitory learning. Emo-
tional processing occurs as a result of these exposures
and changes in cognitions, such as increasing sense of
self-competence and self-control over negative affect and
emotional difﬁculty (i.e., “I can handle bad things that
happen”) and enhancing the experience of social support
(i.e., “other people think I am a good person”).[7–9]
Research supports that trauma survivors who have
lower cortisol in the acute aftermath of trauma expo-
sure may be at a higher risk of PTSD at long-term
followup.[10,11]. This effect may be moderated by prior
trauma exposure, and preliminary studies with cortisol
administration in the acute period following trauma sug-
gest reducedPTSDrates in those receiving cortisol com-
pared to those who received placebo.[10–12] These data
suggest that adequate levels of cortisol in the aftermath
of trauma exposure may facilitate recovery, and that cor-
tisol levels may predict or even inﬂuence outcomes. If
cortisol levels or stress reactivity at entry into treatment
can similarly shape treatment outcomes, efforts to en-
hance levels or reactivity in conjunction with exposure
therapy might further improve PE efﬁcacy.
Several studies have shown that administration of cor-
tisol prior to exposure exercises has resulted in signif-
icantly larger reductions in phobic avoidance and less
increased skin conductance on exposure to phobic sit-
uations than placebo.[13,14] Consistent with these ﬁnd-
ings, Bentz et al.[15] proposed that glucocorticoids may
enhance inhibitory learning, or speciﬁcally enhance the
consolidation of nonfear responding in feared situations
and inhibit retrieval of aversive learning. Altering ex-
posure procedures to tap into processes that enhance
inhibitory learning and/or recall, not simply tolerating
distress, may enhance treatment outcome; and corti-
sol may be a salient “player” in these processes. Few
studies have examined endogenous cortisol secretion
or reactivity over a full course of treatment in PTSD
patients.
We know that the HPA axis is highly reactive to nov-
elty and habituates readily to repeated exposure.[16] This
system is speciﬁcally sensitive to social support and to
cognitive sets associated with sense of competence, con-
trol, and mastery.[16–18] It is possible that HPA axis dys-
regulation is tightly tied to symptom manifestations in
PTSD and that PE may be effective partially because
it addresses phenomena that are “salient” to the HPA
axis. Activity within the HPA axis may be able to pre-
dict treatment response, may be a marker of successful
recovery, or may actively inﬂuence emotional/cognitive
processing in ways that inﬂuence recovery.
We studied the effects of PTSD treatment on PTSD
severity among veterans randomly assigned to PE or an
active comparator (Present-centered Therapy [PCT]),
examining two indices of HPA axis function (corti-
sol awakening response [CAR] and cortisol response
to trauma cues [using script-driven imagery]). CAR
is a readily accessible and commonly used HPA axis
measure. Alterations in CAR are associated with per-
ceived stress,[19,20] and with both PTSD[21] and depres-
sive symptoms.[22] Script-driven imagery[23] taps into
trauma-related reactivity and has been shown to el-
evate plasma cortisol levels in combat veterans with
PTSD.[24,25] We expected greater symptom and cogni-
tion improvement in PE relative to PCT and hypothe-
sized that higher CAR and higher cortisol response to
trauma scripts (prior to treatment) would be associated
with better treatment responses across treatments. We
predicted that high treatment responders compared to
low responders would show higher CAR and lower cor-
tisol response at the end of treatment. Since we expected
potential differences in magnitude of relationship of fac-
tors by treatment, we examined within each treatment
changes in trauma-related cognitions and predicted that
reductions in negative thoughts about the self and world
would be linked to changes in HPA measures and to
symptom change.
MATERIALS AND METHODS
Thirty-six military veterans with signiﬁcant PTSD (CAPS  50)
and reported impairment of at least 3 months duration who presented
to the VAAAHS PTSD Clinical Team were consented. Informed
consent was obtained following explanation of all procedures. As-
sessment included the Mini International Neuropsychiatric Interview
(MINI[26]), and the Clinician-administered PTSD Scale (CAPS[27]).
Evaluators were blind to veteran assignment. To enhance general-
izability, exclusion criteria were minimized and included only con-
traindications for PTSD treatment and factors that would interfere
with the mechanisms under study. Exclusion criteria were the follow-
ing: (1) level of self-harm risk that requires immediate, focused inter-
vention; (2) unmanaged psychosis or bipolar disorder; (3) alcohol or
substance dependence in the past 3 months; (4) working night-shifts;
(5) changes to psychoactive medications in the past 4 weeks; or (6)
taking medication that makes HPA axis measures difﬁcult to interpret.
Veterans were randomly assigned to receive 10 to 12, 80-min sessions
of PE or PCT. In session 10, all veterans were assessed using the Post-
traumatic Diagnostic Scale[28] and those who scored 10 or higher con-
tinued for 12 total sessions. The protocol was approved by the VA Ann
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Arbor Healthcare System Human Subjects Committee and complies
with the Code of Ethics of the World Medical Association.
Assessments occurred at pre-, mid-, and posttreatment. Each as-
sessment included evaluation of symptoms and biological factors. This
report focuses on HPA measures and primary symptom outcomes.
Prior to the ﬁrst major assessment, veterans attended an acclimation
and interview visit in order to reduce novelty response to the labora-
tory environment, create 1-min personal neutral and trauma scripts in
accordance with a standardized script presentation paradigm,[1,23] and
introduce the salivary CAR collection.
On the morning of each assessment, veterans used salivettes to col-
lect saliva samples at awakening and 30 and 45min post awakening and
brought samples to the laboratory that day. In the lab, they heard neu-
tral and personal trauma scripts followed by a 45-min colored block
task to prevent napping. Salivary cortisol collections occurred prior
to the script and 15, 30, and 45 min following each script. Indepen-
dent evaluators completed CAPS interview and veterans completed
self-report forms.
INTERVENTIONS
PE. PE (see manual[29]) includes psychoeducation, exposure to
trauma memories (imaginal exposure), in vivo exposure to trauma-
related avoided situations (in vivo exposure), and emotional processing.
PE has extensive support for its efﬁcacy with combat veteran and other
trauma populations.[5,30]
PCT. PCT followed the Shea manual.[31] PCT matched PE for
number and length of sessions. The ﬁrst two sessions provide psychoe-
ducation about PTSD and the remaining sessions focused on discus-
sion of current experience of PTSD symptoms and coping. The ﬁrst
author served as the only study therapist.
OUTCOME MEASURES
CAPS. CAPS[27] is a standard interview for PTSD severity. Cur-
rent PTSD was assessed in relation to the war-zone trauma that was
currently most upsetting. For PTSD diagnosis, a symptom was rated
as present if the sum of frequency and severity was 4.[32] The CAPS
has excellent psychometrics. Clinically signiﬁcant reduction in PTSD
was deﬁned as reduction in total CAPS of at least 10 points compared
to baseline.[31] For responder status, a more conservative measure of
response was used to better differentiate the groups for detection of
biological differences. We required a 50% reduction in CAPS score
from pre- to posttreatment to be considered a high responder. Aver-
age number of sessions did not differ between responders (M = 10.3,
SD = 1.9) and nonresponders (M = 10.8, SD = 2.5; F (1, 24) = 0.3,
ns).
CAR. CARmeasures HPA response axis upon awakening. Saliva
was collected using salivettes placed in his/her mouth for 30–60 s for
each collection. Veterans were instructed to refrain from eating, drink-
ing, brushing their teeth, or smoking for at least an hour before sam-
pling. Cortisol was assayed using theDiagnostic Products Corporation
(DPC) Coat-a-Count cortisol radioimmunoassay (RIA; Los Angeles,
CA) kit. This 125I RIA method has an intra-assay and inter-variability
of <5%. CAR was calculated as area under the curve (AUC) produced
by the samples taken at awakening, 30 and 45 min after awakening.
Cortisol Response to Script-Driven Imagery. Cortisol re-
sponse to script-driven imagery is a measure of trauma-speciﬁc stress
reactivity. Cortisol level for each of the assays collected during script-
driven imagery was examined. In addition, for total cortisol response
we used the area under the curve above preexposure baseline.
PosttraumaticCognitions Inventory (PTCI). PTCI[33] has 36
items assessing negative thoughts about the self, negative thoughts
about the world, and self-blame. Only the negative thoughts about
the self and world scales are presented here. The scale has good
psychometrics.[8]
ANALYTIC PLAN
Our study focused on biological factors related to treatment re-
sponse, therefore only subjects who received an active dose of therapy
(at least seven sessions and mid- or posttreatment assessment) were
included in the ﬁnal analyses of treatment associated mechanisms of
change. Given the small sample size and hypothesis directed tests, cor-
tisol levels were examinedwith planned independent t-tests as compar-
isons of PE versus PCT and low and high treatment responders within
each assay and time point. Separate repeated measures ANOVAs with
Greenhouse–Geisser corrections and post hoc t-tests examined the
impact of treatment (PE vs. PCT) on PTSD severity. A similar series
of ANOVAs with follow-up t-tests were conducted comparing high
and low treatment responders on cognitions. In addition, standardized
residuals of all of the symptom and mechanisms measures were calcu-
lated to examinemagnitudeof change in each variablewhile controlling
for the multiple assessments.[34] Standardized residuals of these mea-
sures were correlated to examine whether changes in cortisol response
to scripts, CAR, and cognitions were related to symptom change. A
series of regression analyses were conducted within PE and PCT to




Thirty-six veterans were consented (PE, n = 18; PCT,
n = 18; see CONSORT Flowchart and Checklist). Six
of these veterans did not return for any study visit and no
data is available. Twenty-six veterans completed treat-
ment (PE, n = 11, PCT, n = 15; 87% retention). Table 1
presents sample demographics.
EFFECTS OF TREATMENT
Clinically signiﬁcant reductions (>10-point reduction
in CAPS) were seen in 91% of PE and 60% of PCT pa-
tients. Examining conservatively deﬁned high- and low-
responder groups, 64% of PE and 33% of PCT patients
were high responders. PE resulted in signiﬁcantly more
symptom reduction than PCT, though both treatment
groups demonstrated signiﬁcant symptom reduction at
posttreatment (Table 2). Trauma-related negative cog-
nitions (PTCI) showed signiﬁcant reductions over the
course of treatment with no differences between treat-
ment groups (pretreatment data are missing for one vet-
eran, n = 25).
A series of planned t-tests comparing PE and PCT
revealed no group difference in CAR at pre (t (24) = .03,
ns) or midtreatment (t (17) = −1.23, ns). However, at
posttreatment, veterans who received PE showed sig-
niﬁcantly higher CAR compared to those who received
PCT (t (15) = −3.4, P = .004, d = 1.7). A series of
planned t-tests comparing PE and PCT in cortisol level
and response during script-driven imagery revealed no
signiﬁcant differences between groups.
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M (SD) 31.9 (7.6) 31.9 (7.3) 31.36 (7.0)
Gender, n
Male 33 10 14
Female 3 2 0
Race, n (%)
Black 5 (13.9) 1 4
White 30 (83.3) 11 9
Other 1 (2.8) 0 1
Relationship, n (%)
Married 16 (44.4) 4 (33.3) 9 (64.3)
Remarried 4 (11.1) 1 (8.3) 1 (7.1)
Divorced/separated 8 (22.3) 4 (33.3) 1 (7.1)
Never married 5 (13.9) 2 (16.7) 2 (14.3)
Missing 3 (8.3) 1 (8.3) 1 (7.1)
Deployment, n (%)
Afghanistan 8 (22.2) 3 (25.0) 4 (28.6)
Iraq 31 (86.1) 10 (83.3) 11 (78.6)
Service connection, n (%)
PTSD 5 (13.9) 1 (8.3) 3 (21.4)
Medical 10 (27.8) 2 (16.7) 5 (35.7)
Comorbid diagnoses, n (%)
Major depressive episode 17 (47.2) 8 (66.7)* 2 (14.3)*
Panic disorder 5 (13.9) 1 (7.1) 3 (25.0)
Agoraphobia 3 (8.3) 0 2 (16.7)
Social phobia 3 (8.3) 0 2 (16.7)
Alcohol abuse 2 (5.6) 2 (14.3) 0
Generalized anxiety
disorder
2 (5.6) 1 (7.1) 0
∗High and low responders differ (χ2 (1, N = 26) = 7.5, P = .009).
RESPONDER ANALYSES
A series of planned t-tests were conducted compar-
ing high and low treatment responders on cortisol levels
during the script-driven imagery paradigm within each
assessment. These showed that at pretreatment, high
treatment responders showed a trend toward increased
cortisol level at 30 min post trauma script when com-
pared to low responders (t (24) = −1.8, P = .08 [see
Fig. 1A]). At midtreatment, high treatment responders
showed higher cortisol levels throughout the imagery
task, with signiﬁcant elevations as compared to low re-
sponders at initiation of the trauma script and 15, 30,
and 45 min later (t (22) = −2.4, P = .03; 15 min,
t (22) = −2.3, P = .03; 30 min, t (22) = −2.6, P = .02;
45 min, t (22) = −2.2, P = .04 [see Fig. 1B]). At post-
treatment, no differences between high and low treat-
ment responders were detected in cortisol response to
the trauma script task and no difference in levels during
the task (see Fig. 1C).Therewere no differences between
high and low treatment responders in CAR at any time
point.
High and low responders differed signiﬁcantly in cog-
nitive changes (PTCI) over the course of treatment.
Thoughts of incompetence to handle negative affect and
thoughts of a generally dangerous world signiﬁcantly
improved over time in high responders but showed no
change in low responders (see Table 2).
TREATMENT CHANGE IN SYMPTOMS,
COGNITIONS, AND CORTISOL
Prior to treatment, higher CAPS PTSD symptom
severity was associated with higher cortisol total re-
sponse to the trauma script task (r (26) = .39, P = .05)
and with lower CAR (r (31) = −.40, P = .03). These re-
lationships were lost at mid- and posttreatment. Higher
cortisol responses to the trauma script exposure prior
to treatment signiﬁcantly predicted enhanced treatment
symptom improvement (r (26) = −.40, P < .05); and
treatment response was signiﬁcantly associated with re-
ductions in negative thoughts about the self (r (21)= .70,
P = .001). Other cortisol measures did not predict symp-
tom change.
To further examine the role of outcome predictors
within each treatment, two separate series of multi-
ple regressions (PE and PCT) investigated relationships
among cognitive changes, pretreatment cortisol mea-
sures, and symptom change (see Table 3). Each treat-
ment was examined in three models including just the
factor by itself (script-associated cortisol response, CAR,
and change in negative thoughts about the self) predict-
ing symptom change. In PCT, treatment change was
predicted only by change in negative thoughts about the
self. As such, no additional models were conducted. In
PE, all three factors showed signiﬁcant relationship to
symptom change. Thus, we analyzed the two cortisol
measures together to see their contributions to symp-
tom change. This analysis suggested a suppression ef-
fect where both factors were nonsigniﬁcant predictors
when included together. To clarify, we then examined
each cortisol measure combined with change in negative
thoughts about the self predicting symptom change, to
isolate a unique cortisol effect while controlling for im-
portant cognitions. Script-associated cortisol response
prior to treatment and reductions in negative thoughts
about the self over treatment each made signiﬁcant,
unique, and large contributions to prediction of PTSD
symptom change. The ﬁnal model accounted for 83% of
the variance in PTSD symptom change, with both cog-
nitive change (43% unique variance) and cortisol levels
(22% unique variance) contributing signiﬁcantly to out-
come variance. When CAR was combined in a multiple
regression with change in negative thoughts about the
self, cognitive change predicted improvement but CAR
did not.
DISCUSSION
The current study is unique in its examination of
changes in HPA axis function over PTSD treatment and
inclusion of trauma-related cognitions and PTSD symp-
toms.High treatment responders showed a trend toward
higher cortisol level to their personal trauma script at
pretreatment. Further, in regression analyses predicting
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Figure 1. (A) Cortisol response to trauma scripts by posttreatment responder status at pretreatment. (B) Cortisol response to trauma
scripts by posttreatment responder status at midtreatment. (C) Cortisol response to trauma scripts by posttreatment responder status
at posttreatment.
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TABLE 2. Means (and SD) for completers and responders samples by time point and condition
Assessment
Pre Mid Post
Condition PE PCT PE PCT PE PCT
CAPS
CAPS Total score*
M (SD) 79.2 (12.1) 77.4 (12.1) 50.5 (20.0) 65.5 (20.0) 30.0 (18.4) 53.6 (28.7)
n 11 15 11 15 11 15
Posttraumatic Cognitions Inventory
PTCI Total**
M (SD) 121.9 (27.2) 117.4 (32.3) 106.8 (32.9) 110.2 (35.0) 91.3 (41.9) 97.1 (45.6)
n 11 14 11 14 11 14
PTCI Selfa
M (SD) 3.7 (1.0) 3.5 (1.2) 3.0 (1.2) 3.3 (1.2) 2.5 (1.4) 2.8 (1.4)
n 11 14 11 14 11 14
PTCI Worldb
M (SD) 5.3 (1.0) 4.9 (1.2) 5.1 (1.4) 4.6 (1.3) 4.6 (2.1) 4.1 (1.8)
n 11 14 11 14 11 14
Pre Mid Post
Treatment response High Low High Low High Low
PTCI Total†
M (SD) 118.3 (35.0) 120.4 (25.1) 89.1 (28.5) 126.8 (27.3) 61.0 (24.4) 125.5 (31.9)
n 12 13 12 13 12 13
PTCI Self††
M (SD) 3.6 (1.3) 3.5 (0.9) 2.5 (1.0) 3.8 (1.0) 1.5 (0.5) 3.7 (1.1)
n 12 13 12 13 12 13
PTCI World†††
M (SD) 4.9 (1.7) 5.1 (0.9) 4.4 (1.5) 5.2 (1.0) 3.4 (2.2) 5.1 (1.2)
n 12 13 12 13 12 13
Note: Intent to treat analysis with CAPS, Time × Treatment, F (2, 56) = 2.6, P = .08.
∗CAPS, Time × Treatment, F (1.5, 36.4) = 6.4, P = .008. Follow-up t-tests, midtreatment (t (24) = 1.9, P = .07, d = .75) and posttreatment
(t (24) = 2.4, P = .03, d = .98). Pre to post Cohen’s d, PE = 3.16; PCT = 1.08.
∗∗PTCI Total, Time main effect, F (1.3, 29.0) = 6.5, P = .01, d = 0.67.
aPTCI, negative thoughts about the self, Time main effect, F (1.3, 30.5) = 6.4, P = .01, d = .79.
bPTCI, negative thoughts about world, Time main effect, F (1.2, 28.0) = 5.8, P = .02, d = .45.
†PTCI, Total, Time × responder, F (1.4, 33.3) = 16.8, P = .000. Pre to post Cohen’s d, high = 1.9; low = −0.18. Follow-up t-tests, pre = ns; mid,
t (24) = 3.1, P = .004, d = 1.3; post, t (24) = 5.4, P = .000, d = 2.27.
††PTCI, negative thoughts about the self, Time × Responder, F (1.6, 35.8) = 16.8, P = .000. Pre to Post Cohen’s d, high = 2.13; low = −0.30.
Follow-up t-tests, pre = ns; mid, t (24) = 3.0, P = .006, d = 1.3; post, t (24) = 6.0, P = .000, d = 2.49.
†††PTCI, negative thoughts about the world, Time × Responder, F (1.3, 29.9) = 8.2, P = .004. Pre to post Cohen’s d, high = 1.9; low = 0.17.
reductions in PTSD severity with PE, pretreatment cor-
tisol response to personal trauma script predicted 40%
of the variance in change in PTSD severity. Although
change in negative thoughts about the self was a signiﬁ-
cant predictor of change in PTSDwith both treatments,
this cortisol response to trauma script was speciﬁc in
predicting PTSD change in PE only. As such, increased
self-efﬁcacy is related to treatment response across these
different treatment models, but the HPA axis was specif-
ically relevant to response in PE. Thus, our data support
the idea that during PE activation of cortisol response
may open a window of plasticity that then allows in-
hibitory learning and changes in trauma-related cogni-
tions to occur resulting in reductions in PTSD.
Consistent with previous studies suggesting that
trauma survivors who are able to mount a cortisol
response may be more likely to recover (either natu-
rally or with treatment), our results illustrate how this
may occur. In high treatment responders, at pretreat-
ment, we see initial cortisol level elevation at 30 min
post script, and in contrast, no cortisol response in the
low-responder group. This ﬁnding is apparent despite
the brief nature of the trauma cue (1-min audio script).
At midtreatment, this separation between high and low
responders becomes more pronounced with groups sep-
arating in their cortisol levels throughout the research
session. One can speculate that this separation is poten-
tially a function of the degree of emotional engagement
in the imaginal and in vivo exposures in therapy. As they
are more engaged in the work of therapy, their HPA axis
is more activated. However, this is preliminary given
the small sample size in the current study. Finally, at
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TABLE 3. Prediction of change in CAPS from
cognitions, script-driven cortisol, and CAR in PCT and
PE
Model and variable R β SE F/t P
PCT
Model 1 (n = 14) 0.10 – – 0.14 ns
SA-Cort – −0.10 195.8 −0.37 ns
Model 2 (n = 14) 0.28 – – 5.56 ns
CAR – 0.28 15.4 1.05 ns
Model 3 (n = 12) 0.70 – – 10.26 .01
Self – −0.70 5.56 −3.20 .01
PE
Model 1 (n = 10) 0.63 – – 6.00 .04
SA-Cort – 0.63 75.54 2.45 .04
Model 2 (n = 10) 0.64 – – 6.30 .03
CAR – −0.64 12.02 −2.51 .03
Model 3 (n = 7) 0.78 – – 9.26 .02
Self – −0.78 4.54 −3.04 .02
Model 4 (n = 10) 0.80 – – 5.45 .03
SA-Cort – 0.45 73.73 1.76 .12
CAR – −0.46 11.85 −1.83 .11
Model 5 (n = 7) 0.91 – – 11.73 .01
SA-Cort – 0.49 45.61 2.49 .05
Self – −0.63 3.49 −3.21 .02
Model 6 (n = 7) 0.81 – – 4.64 .07
CAR – −0.21 15.34 −.78 ns
Self – −0.73 4.80 −2.71 .04
ns, anyP-values of .15 or higher. Script-AssociatedCortisol (SA-Cort).
posttreatment, again there are no differences between
the groups and both groups appear to have overall min-
imal cortisol levels. At this point, for those veterans
who have highly responded to treatment, trauma cues
no longer evoke a cortisol response, whereas the low-
responder group maintains the same pattern of contin-
ued low cortisol levels. If, indeed, the absence of cor-
tisol level increase at pre and midtreatment reﬂects a
biomarker of absence of emotional engagement, it could
be important to explore whether the low treatment re-
sponders are showing a conscious avoidance and pushing
away of the emotional memory content, or a less volun-
tary “dissociation-like” response when confronted with
the memory content. On the other hand, it is possible
that it represents a physiological inability to mount cor-
tisol response during the memory task. Additional study
is needed to replicate and clarify these results in a larger
sample.
This observed lack of cortisol response to trauma cues
may represent a preexisting risk factor for PTSD or
an alteration in function that occurs posttrauma. Such
a distinction has implications for how and if it can be
modiﬁed with intervention. However, if it is possible to
use a pretreatment script-driven imagery paradigm to
identify those who are likely to become low treatment
responders and use augmentation to “jump start” their
cortisol response to cues while providing PTSD treat-
ment, more patients may respond to effective treatment.
Such increased effectiveness may come through higher
retention as response comes more quickly or larger re-
ductions in symptoms for previous partial responders.
Indeed, in trauma-focused therapies emotional engage-
ment with the memory has been put forward as a criti-
cal element for efﬁcacy.[29] However, research examining
this mechanism has been largely reliant on self-report of
distress from the patient and results have been incon-
sistent. Cortisol response to the trauma script may be a
biomarker of this process mechanism.
In addition, our data replicate the association between
pretreatment PTSD severity and CAR and cortisol re-
sponse to personal trauma script at pretreatment, validat-
ing the representativeness of our sample, and potential
generalizability of our ﬁndings. Speciﬁcally, as demon-
strated in other samples of trauma survivors, PTSD is re-
lated to a ﬂattening of CAR[35] and increased responsive-
ness to personal trauma script.[1] Although these ﬁndings
might be consistent with the notion that PTSD is asso-
ciated with less pronounced HPA diurnal response, they
do not suggest overall decreased HPA responsivity, as
evidenced by the increased cortisol response to a trauma
speciﬁc challenge task.
With regard to treatment-type analyses, both treat-
ments showed signiﬁcant reduction in PTSD symptoms
from pre- to posttreatment. However, changes related
to PE were signiﬁcantly larger than PCT, with 91% of
the PE group showing clinically signiﬁcant reduction
in PTSD and only 60% in the PCT condition meet-
ing that criterion. Further, the PE group showed sig-
niﬁcantly larger CAR response at posttreatment than
the PCT group. Thus, PE may impact a PTSD-related
HPA axis–associated dysfunction. Recently, PTSD pa-
tients randomized to receive D-cycloserine (DCS) prior
to PE evidenced a lower cortisol and startle response
to a fear potentiated startle paradigm at posttreatment
than those who did not get DCS,[36] also demonstrating
alteration in HPA axis function with PE.
Several caveats are warranted. The current sample is
small and effects may not have been detected. Our sam-
ple is composed wholly of veterans andwhether these re-
sults generalize to other PTSD treatment samples is un-
clear.With regard to CAR, based on patient burden and
study budget, we were limited to assessment of CAR on
a single morning. Replication with assessment on three
consecutive mornings may increase conﬁdence in the
effect.[37]
CONCLUSIONS
Speciﬁc alterations in HPA axis response to diurnal
processes (CAR) and speciﬁc trauma cues are related to
PTSD treatment response within PE. In addition, re-
ductions in negative thoughts about the self and world
are related to reductions in PTSD symptoms in both PE
and PCT. As the neurobiological mechanisms are char-
acterized, therapeutic techniques can be targeted and
more efﬁciently delivered, allowing more patients access
as treated cases respond in fewer sessions and allowing
reduction in drop out as patient burden is reduced.
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